Postoperative presentation % (N) or mean/median (SD/IR) | Ependymoma (13) | Subependymoma (21) | Central Neurocytoma (10) | GEC (1) | Total (45) |
---|---|---|---|---|---|
Gross total resection | 84.6% (11) | 100% (21) | 90.0% (9) | 100% (1/1) | 93.3% (29) |
New neurological deficits | Vigilance 7,.% (1) Ataxia 15.4% (2) | Ataxia 14.3% (3) | Hemiparesis 20.0% (2) Dysarthria 20.0% (2) Tinnitus 10.0% (1) Vigilance 10.0% (1) | 0 | 26.6% (12) |
New cranial nerve deficits | IX 7.7% (1) XII 7.7% (1) | VII 4.8% (1) IX 4.8% (1) XII 4.8% (1) | 0 | 0 | 11.1% (5) |
Post-operative KPSS | 90% (IR 70–100) | 100% (IR 85–100) | 90% (IR 87,5–100) | 100% | 90% (IR 80–100) |
KPSS unchanged | 61.5% (8) | 38.1% (8) | 60.0% (6) | 0 | 48.9% (22) |
KPSS declined | 23.1% (3) | 19.0% (4) | 20.0% (2) | 0 | 20.0% (9) |
KPSS improved | 15.4% (2) | 42.9% (9) | 20.0% (2) | 100% (1) | 31.1% (14) |
Clavien Dindo Scale (CDG) | 1 (IR 1–1,25) | 1 (±IR 1–2) | 2 (IR 1–3) | 1 | 1 (IR 1–2) |
Complications | CSF leakage 7.7% (1) | Ventriculitis/Meningitis 9.5% (2) Death 4.8% (1) | Ventriculitis/ Meningitis 40.0% (4) Ventr. entrapment 10.0% (1) | 0 | 20.0% (9) |
Shunt/cisternostomy dependency | 15.4% (2) | 4.8% (1) | 30.0% (3) | 0 | 13.3% (6) |
Follow-up time in months | 16.4 (±14,1) | 316 (±33) | 26,.4 (±36,9) | 72 | 26,9 (±30.1) |